Company intelligence / Profile preview

PharmaLedger Association

Basel, Basel-Stadt, Switzerlandpharmaledger.org ↗

Ownership: Private
Development stage: Commercial

Overview

PharmaLedger Association has successfully transitioned from an EU-funded research project into an active non-profit that brings together over 30 members from pharma companies, tech providers, academia, government agencies, and patient organizations. Its main achievements include developing blockchain-based solutions for electronic product information delivery, anti-counterfeit features in supply chains, eConsent forms for clinical trials digitization, and frameworks for secure health data sharing[1][3][5]. The ePI solution is being launched as the first production use case.

Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Takeda PharmaceuticalsTechnovative SolutionsImprensa Nacional Casa da MoedaDemocritus University of ThraceCSCMP Roundtable Switzerland

Beyond the preview

Go deeper on PharmaLedger Association.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmaLedger Association.

Explore the full profile